A Phase 2 interventional study of iloperidone and Placebo in Hypertension and Uncontrolled Hypertension, sponsored by Vanda Pharmaceuticals. Recruiting at 28 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 569th largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 99 that started in 2025, is one of 170 in phase 2, reaches primary completion later than 70 of the 367 other live ones, and was the 1,908th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 99 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: iloperidone
Drug: Placebo
iloperidone
Also known as: Fanapt
placebo comparator
Change from baseline to treatment week 4 in SiSBP
Time frame: screening to treatment week 4
Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 13 months is close to that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloperidone